· Operations focused on the laquinimod projects and organization adjusted accordingly
Laquinimod
· The pivotal CONCERTO clinical Phase III study in relapsing remitting MS (RRMS) is fully enrolled and results are expected in 2017
· The first patient was enrolled for the ARPEGGIO Phase II study, which will evaluate laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
· The Phase II study LEGATO-HD into Huntington's disease is proceeding according to plan
· Laquinimod presented by Teva at the AAN Annual Meeting on April 18-25, 2015
Tasquinimod
· Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod significantly reduced the risk of radiographic cancer progression compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28).
· Further development of tasquinimod discontinued and the collaboration agreement with Ipsen terminated
ISI
· Only commercial activities will be conducted from 2016
Financial summary
| MSEK | April - June | Jan. - June | Jan. - Dec. | |||||
| 2015 | 2014 | 2015 | 2014 | 2014 | ||||
| Net sales | 3.2 | 2.7 | 6.1 | 4.9 | 10.4 | |||
| Operating loss | -70.1 | -57.9 | -127.5 | -117.2 | -228.5 | |||
| Loss for the period | -71.4 | -57.7 | -129.3 | -117.9 | -231.5 | |||
| Loss per share (SEK) | -0.79 | -0.77 | -1.44 | -1.57 | -3.02 | |||
| Cash and cash equivalents | 186.6 | 227.7 | 328.5 | |||||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
The report is also available at www.activebiotech.com
Active Biotech AB
Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
